After a kidney transplant, patients take drugs called anti-rejection drugs (immunosuppressives) to prevent their bodies from rejecting the new kidney. At present it is not possible to have a successful transplant without these drugs. These drugs make it possible for a person who receives the transplant to accept the "foreign" kidney. Most patients who get a transplant need to take anti-rejection medications for the rest of their lives, or for as long as the kidney continues to work. Researchers are looking to learn whether abatacept is as good as belatacept in preventing rejection, whether there are other benefits or harms associated with abatacept treatment, and possibly allows greater flexibility on patient's travel and time since abatacept is self-administered at home. This study is being done to answer these questions: Are weekly abatacept injections under the skin a safe and effective substitute for monthly belatacept intravenous (IV) infusions? and How well does the kidney function after switching from belatacept to abatacept?
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants Who Are Compliant With Self-administration
Timeframe: Up to 12 months post-transplantation, an average of 8 months
Number of Participants Who Remain Free of Biopsy-proven Acute T-cell Mediated Rejection (aTCMR) or Antibody-mediated Rejection (ABMR) as Defined by Banff Criteria at or Before 12 Months After Transplantation.
Timeframe: Up to 12 months post-transplantation, an average of 8 months
Number of Participants Presenting Serious Adverse Events
Timeframe: Up to 12 months post-transplantation, an average of 8 months
Number of Participants With Serious Infections
Timeframe: Up to 12 months post-transplantation, an average of 8 months
Number of Patients With Cytomegalovirus (CMV) Viremia Stratified by the Magnitude
Timeframe: Up to 12 months post-transplantation, an average of 8 months
Number of Patients With BK Viremia Stratified by the Magnitude
Timeframe: Up to 12 months post-transplantation, an average of 8 months
Number of Participants Who Develop Any Malignancy
Timeframe: Up to 12 months post-transplantation, an average of 8 months